Yes, Sprycel Treats Leukemia
Sprycel (dasatinib) is a targeted therapy approved for specific types of leukemia, primarily chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It inhibits the BCR-ABL tyrosine kinase enzyme that drives cancer cell growth in these blood cancers.[1]
What Types of Leukemia Does Sprycel Target?
Sprycel is FDA-approved for:
- Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic phase CML.
- Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML resistant or intolerant to prior therapy like imatinib (Gleevec).
- Adults with Ph+ ALL in combination with chemotherapy.
- Children aged 1 and older with Ph+ CML in chronic phase.[2]
It is not approved for other leukemias like acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL).
How Does Sprycel Work Against Leukemia?
Sprycel blocks signals that allow leukemia cells to multiply uncontrollably. In CML and Ph+ ALL, a genetic abnormality creates the BCR-ABL fusion protein, which Sprycel targets more potently than first-generation drugs like imatinib, especially against resistant mutations.[1][2]
Common Side Effects Patients Report
Frequent issues include low blood cell counts (myelosuppression), fluid retention, diarrhea, headache, fatigue, and pleural effusion (fluid around lungs). Serious risks involve pulmonary arterial hypertension and QT prolongation. Monitoring is required.[2]
How Does Sprycel Compare to Gleevec?
Both treat Ph+ CML, but Sprycel handles more T315I mutations and has faster responses in some resistant cases. Gleevec is first-line for newly diagnosed due to its safety profile; Sprycel is second-line or for intolerance.[3]
| Feature | Sprycel (Dasatinib) | Gleevec (Imatinib) |
|---------|---------------------|---------------------|
| Dosing | 100 mg once daily | 400 mg once daily |
| Resistance | Better for certain mutations | More common resistance |
| Side Effects | More pleural effusion | More nausea, rash |
When Does Sprycel Patent Expire?
Key U.S. patents on dasatinib expired in 2025, opening doors for generics. Pediatric exclusivity adds six months, pushing full generic entry to late 2025 or 2026 amid ongoing litigation.[4]
Who Makes Sprycel and Generic Alternatives?
Bristol Myers Squibb manufactures Sprycel. No U.S. generics are approved yet, but challenges from Teva and others are pending.[4]
[1]: FDA Label for Sprycel
[2]: NCCN Guidelines for CML
[3]: NEJM Study on Dasatinib vs Imatinib
[4]: DrugPatentWatch.com - Sprycel Patents